Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hong Kong's Ally Bridge Invests in Two European Biopharmas

publication date: Feb 21, 2017
Ally Bridge Group announced it has made investments in two European biopharmas: Galenica AG of Switzerland, and Nabriva , an Austrian-US pharma. Galenica's subsidiary Vifor Pharma, makes iron supplements and other products for chronic kidney disease. Nabriva develops next-gen antibiotics for bacterial infections, especially drug-resistant bacteria. Ally has $1.5 billion under management, all in life science companies, which are located in the US, Europe and China. It did not disclose the size of either investment. More details....

Stock Symbols: (SIX: GALN) (NSDQ: NBRV)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital